Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 180 58% Improvement Relative Risk Mortality, day 30 79% Ventilation 48% ICU admission 56% Hospitalization, day 180 7% Hospitalization, day 30 34% c19early.org/pl Bajema et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes
Bajema et al., medRxiv, doi:10.1101/2022.12.05.22283134 (Preprint)
Bajema et al., Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target.., medRxiv, doi:10.1101/2022.12.05.22283134 (Preprint)
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 112,380 high-risk patients in the USA, showing lower mortality with paxlovid treatment. The title and headers of Table S14 are conflicting but the data appears to match the title.
[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of death, 58.0% lower, HR 0.42, p < 0.001, treatment 20 of 1,587 (1.3%), control 48.6 of 1,587 (3.1%), NNT 55, cumulative 0-180 days, propensity score matching, day 180, Table S14.
risk of death, 78.8% lower, RR 0.21, p < 0.001, treatment 5 of 1,587 (0.3%), control 23.6 of 1,587 (1.5%), NNT 85, propensity score matching, day 30.
risk of mechanical ventilation, 48.3% lower, RR 0.52, p = 0.51, treatment 3 of 1,587 (0.2%), control 5.8 of 1,587 (0.4%), NNT 567, propensity score matching, day 30.
risk of ICU admission, 56.1% lower, RR 0.44, p = 0.03, treatment 10 of 1,587 (0.6%), control 22.8 of 1,587 (1.4%), NNT 124, propensity score matching, day 30.
risk of hospitalization, 7.0% lower, HR 0.93, p = 0.53, treatment 180 of 1,587 (11.3%), control 194.2 of 1,587 (12.2%), NNT 112, cumulative 0-180 days, propensity score matching, day 180, Table S14.
risk of hospitalization, 34.0% lower, RR 0.66, p = 0.03, treatment 43 of 1,587 (2.7%), control 65.2 of 1,587 (4.1%), NNT 71, propensity score matching, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bajema et al., 6 Dec 2022, retrospective, USA, preprint, median age 67.0, 18 authors, study period 1 January, 2022 - 28 February, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.12.05.22283134; this version posted December 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes Kristina L. Bajema, MD, MSc1,2; Kristin Berry, PhD3; Elani Streja, PhD4; Nallakkandi Rajeevan, PhD4,5; Yuli Li, MS4; Lei Yan, PhD4,6; Francesca Cunningham, PharmD7; Denise M. Hynes, MPH, PhD, RN8,9; Mazhgan Rowneki, MPH8; Amy Bohnert, PhD, MHS10,11; Edward J. Boyko, MD, MPH12; Theodore J. Iwashyna, MD, PhD10,13; Matthew L. Maciejewski, PhD14,15,16; Thomas F. Osborne17,18; Elizabeth M. Viglianti MD, MPH, MSc10,19; Mihaela Aslan, PhD4,20; Grant D. Huang, MPH, PhD21; George N. Ioannou, BMBCh, MS3,22 1. Veterans Affairs Portland Health Care System, Portland, OR 2. Division of Infectious Diseases, Department of Medicine, Oregon Health and Sciences University, Portland, OR 3. Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA 4. Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP-CERC), Veterans Affairs Connecticut Healthcare System, West Haven, CT 5. Yale Center for Medical Informatics, Yale School of Medicine, New Haven, CT 6. Department of Biostatistics, Yale School of Public Health, New Haven, CT 7. Veterans Affairs Center for Medication Safety - Pharmacy Benefit Management (PBM) Services, Hines, IL 8. Center of Innovation to Improve Veteran Involvement in Care (CIVIC), VA Portland Healthcare System, Portland, OR 9. Health Management and Policy, School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences; Health Data and Informatics Program, Center for Quantitative Life Sciences, Oregon State University, Corvallis, OR 10. Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI 11. Department of Anesthesiology, University of Michigan, Ann Arbor, MI 12. Seattle Epidemiologic Research and Information Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 13. Schools of Medicine and Public Health, Johns Hopkins, Baltimore, MD 14. Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Medical Center, Durham, NC 15. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC 16. Duke-Margolis Center for Health Policy, Duke University, Durham, NC 17. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 18. Department of Radiology, Stanford University School of Medicine, Stanford, CA 19. Department of Internal Medicine, University of Michigan, Ann Arbor, MI 20. Department of Medicine, Yale School of Medicine, New Haven, CT 21. Office of Research and Development, Veterans Health Administration, Washington, DC 22. Divisions of Gastroenterology, Veterans Affairs Puget Sound Healthcare System and University of Washington, Seattle, WA Primary Funding Source: U.S. Department of Veterans Affairs 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi:..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit